INTRODUCTION

The incidence of gastroesophageal junction (GEJ) cancer is increasing globally.\textsuperscript{1,2} Previous studies suggest that patient prognosis is less favorable in GEJ cancer compared with gastric cancer, even after curative surgical resection.\textsuperscript{3} This may reflect the more difficult surgical approach required or the more complicated metastatic spread that occurs due to the anatomical features of the GEJ.\textsuperscript{4} A recent
Japanese multicenter cohort study undertook lymph node metastasis mapping in GEJ cancer patients. This study recommended basing the extent of lymph node dissection on the estimated length of esophageal invasion. However, the optimal surgical approach for GEJ cancer resection is still controversial, especially when the esophageal invasion length is between 2 and 4 cm. The transhiatal approach has been performed in most surgical resections of GEJ cancer in Japan, but reconstruction is technically challenging. Therefore, the safest method that provides clean surgical margins and does not cause post-surgical gastroesophageal reflux is still under debate.

The prevalence of hiatal hernia (HH) is also increasing, due to our aging population and the rising global prevalence of obesity. In HH, the cardia herniates into the mediastinum via the hiatus. HH can coexist with GEJ cancer. Clinically, the presence of HH can make the preoperative diagnosis of GEJ cancer difficult, for example estimating the anatomical tumor location or the esophageal invasion length. Misidentification of the anatomical tumor location may make transhiatal surgery much more complicated and lead to a higher rate of postoperative complications. For example, unexpected high-level esophageal resection forces challenging intra-mediastinal anastomosis. Development of severe postoperative complications is known to be a critical risk factor for the long-term prognosis of all types of cancer. In addition, the lymphatic drainage route may be altered due to the presence of HH. Therefore, HH may influence not only short-term but also long-term outcomes in patients with GEJ cancer.

In this context, we hypothesized that the presence of HH may adversely affect surgical and survival outcomes in patients with GEJ cancer. Few studies have examined the link between HH and survival outcomes in GEJ cancer patients. This study aimed to assess the impact of HH on the surgical and survival outcomes in patients with GEJ cancer.

### METHODS

#### 2.1 Patients

Patients who underwent R0 surgery via the transhiatal approach (total/proximal gastrectomy and lower esophageal resection with lower mediastinal lymphadenectomy) for primary GEJ adenocarcinoma (with an epicenter within 2 cm of the GEJ) at the National Cancer Center Hospital East, Japan, from January 2008 to December 2017 were included in this study. The clinical data of these patients were reviewed using an in-house database. The exclusion criteria were as follows: (1) patients who received preoperative chemotherapy; (2) conversion surgery for cStage IVB patients; (3) presence of other primary malignant disease; (4) GEJ cancer at the remnant stomach; (5) R1/R2 resection. This study was approved by the Institutional Review Board of the National Cancer Center Hospital East.

#### 2.2 Definition and assessment of HH

The presence of HH was diagnosed by preoperative endoscopy and barium contrast X-ray. The degree of HH was graded according to Makuuchi's classification using endoscopic findings. This classification is as follows from the most severe: Grade A) gastric mucosa is seen more than 3 cm above the hiatus; Grade B) gastric mucosa is seen circularly less than 3 cm above the hiatus; Grade C) gastric mucosa is seen partially above the hiatus; Grade D) the mucosal junction is seen below the hiatus. Following this classification, the patients were divided into a HH (+) group and a HH (-) group. The diagnosis was made by a board-certified fellow of the Japan
Gastroenterological Endoscopy Society with abundant experiences of esophageal/gastric cancer treatment.

2.3 | Assessment of clinical parameters

The macroscopic type and tumor staging followed the Japanese classification of gastric carcinoma: 3rd English edition.\(^\text{13}\) Postoperative complications were graded following the Clavien-Dindo classification, and grade >II complications were recorded in this study.\(^\text{14}\) Anastomotic leakage, intra-abdominal abscess formation, and pancreatic fistula were categorized as "intra-abdominal infectious complication."

2.4 | Statistical analysis

The Student’s t-test or Fisher’s exact test were used to assess the differences in characteristics between the two groups. Survival curves were drawn using the Kaplan-Meier method, and differences were determined by the log-rank test. Univariate and multivariate analyses were performed with a Cox hazard model to detect the independent prognostic factors. All statistical analyses were performed using the JMP software program, version 15 (SAS Institute). All P-values were two-sided, and \(P < .05\) was considered statistically significant.

3 | RESULTS

3.1 | Clinicopathological characteristics

In total, 84 patients were screened from the database. A total of six patients were excluded, therefore 78 patients were included in this study. According to the Makuuchi classification, the degree of HH in these 78 patients was as follows: seven patients had Grade A; 21 patients had Grade B; 18 patients had Grade C; and 32 patients had Grade D. Therefore, 46 patients were assigned to the HH (+) group and 32 patients to the HH (-) group (Figure 2). The clinicopathological characteristics of patients in the HH (+) and the HH (-) group are summarized in Table 1. Patients in the HH (+) group were slightly older than those in the HH (-) group (69.0 vs 67.5 years old, \(P = .018\)). There was no significant difference in the body mass index, histological type, cT factor, cN factor, tumor size, or esophageal invasive length between the two groups. The median length of esophageal invasion was 10 mm (range: 0-40 mm). In terms of surgical approach, 58% (45/78) of patients underwent total gastrectomy and 42% (33/78) underwent proximal gastrectomy. Similarly, 62% (48/78) of patients underwent open surgery and 38% (30/78) underwent laparoscopic surgery.

3.2 | Surgical outcomes

Surgical outcomes of the HH (+) and the HH (-) groups are shown in Table 2. No significant difference was seen in operative time or intraoperative blood loss between the two groups. Additional intraoperative resections of the esophageal stump due to a tumor-positive margin diagnosed by frozen section was more frequent in the HH (+) group (19.6% vs 6.3%, \(P = .082\)), but this did not reach statistical significance. There was no patient who needed conversion to thoracic approach. In terms of postoperative complications, intra-abdominal infectious complications (leakage, intra-abdominal abscess, and pancreatic fistula) was more common in the HH (+) group than in the HH (-) group (23.9% vs 9.4%, \(P = .089\)), but this did not reach statistical difference. However, the incidence of intra-abdominal abscess in the HH (+) group was significantly higher than that in the HH (-) group (17.4% vs 3.1%, \(P = .036\)).

3.3 | Survival outcomes

The median follow-up period was 46.5 (4-113) months in the HH (+) group and 60.0 (10-107) months in the HH (-) group, respectively.
The overall survival (OS) and relapse-free survival (RFS) was compared between the HH (+) and the HH (−) groups. Both OS and RFS were slightly lower in the HH (+) group than in the HH (−) group, but this did not reach statistical difference (Figure 3A). Selection bias was suspected, so we further analyzed the survival outcomes in stratified cohorts according to clinical T factors. In patients with T1-2, the survival curves were similar (OS: P = .789, RFS: P = .503). However, in patients with T3-4, the survival outcomes were significantly worse in the HH (+) group than in the HH (−) group, both in terms of the OS (P = .036, hazard ratio [HR]: 3.06, 95% confidence interval [CI]: 1.02-9.18) and the RFS (P = .039, HR: 2.96, 95% CI: 0.99-8.89) (Figure 3B). Next, we analyzed the patients in stratified cohorts according to pathological stage of disease. In patients with pStage I, survival curves were almost the same (OS: P = .631, RFS: P = .631). However, in pStage II/III, the survival outcomes were worse in the HH (+) group, both in terms of the OS (P = .103, HR: 2.34, 95% CI: 0.81-6.75) and the RFS (P = .119, HR: 2.25, 95% CI: 0.78-6.49) (Figure 3C).

### 3.4 Multivariate analyses in patients with T3-4

Consequently, univariate and multivariate analyses were carried out to detect prognostic factors in patients with T3-4 tumors using the Cox proportional hazard model (Table 3). If the P-value of a factor in univariate analysis was lower than 0.05, that variable was further analyzed in the multivariate analysis. Histological type (undifferentiated), esophageal invasive length (>20 mm), and coexistence of HH were identified as poor prognostic factors for OS. In the subsequent multivariate analysis, esophageal invasive length (>20 mm) (hazard ratio [HR] 4.81; 95% confidence interval [CI] 1.30-17.8, P = .014) and coexistence of HH (HR 3.60; 95% CI 1.06-11.9, P = .032) were identified as independent prognostic factors. In the same analysis for RFS, the univariate analysis showed pathological T3-4, pathological N (+), histological type (undifferentiated), esophageal invasive length (>20 mm), and coexistence of HH as prognostic factors for lower RFS. In the subsequent multivariate analysis, esophageal invasive length (>20 mm) was identified as an independent prognostic factor (HR 4.09; 95% CI 1.11-15.0, P = .034).

### 3.5 Recurrence

The recurrence rates during the follow-up period in the HH (+) and the HH (−) groups were 29.1% and 21.9%, respectively. The distribution of recurrence sites is summarized in Table 4. Mediastinal and paraaortic lymph node metastases tended to be more common in the HH (+) group (33% vs 14%, P = .30), but this did not reach statistical significance. Similarly, peritoneal recurrence was more common in the HH (+) group (58% vs 14%, P = .06).

### 4 DISCUSSION

This study showed that HH is associated with increased postoperative complications after GEJ cancer surgery. Intra-abdominal abscesses were more common in the HH (+) group. Furthermore, HH was correlated with unfavorable survival outcomes after GEJ cancer surgery,
particularly in patients with advanced disease. These findings suggest that HH adversely affects the treatment outcomes of patients with GEJ cancer, and special consideration is required when treating such patients. Increased postoperative complications indicate that HH increases surgical difficulty. To the best of our knowledge, this is the first study to describe this issue focusing on GEJ cancer.

The GEJ is anatomically defined as a boundary between the esophageal and stomach muscular layers. The level of the GEJ should be almost identical with that of the esophageal hiatus, but the GEJ is displaced into the mediastinum in patients with HH. Esophageal invasion length is known to be a critical parameter when deciding the surgical approach or the extent of lymph node dissection required. In patients with HH, a discrepancy may happen; that is, the tumor may be located further away from the hiatus than the estimated esophageal invasion length. In fact, additional resection of the esophageal stump was more frequently required in the HH (+) group in this study. Such a situation makes transhiatal anastomosis much more challenging, which may have contributed to the higher incidence of postoperative complications seen in HH (+) patients in this study.

As expected, the HH (+) group also had less favorable survival outcomes than the HH (−) group. One possible explanation may be the association between increased postoperative complications and poorer survival outcomes. Several publications have suggested that postoperative complications have an adverse impact on survival outcomes in cancer surgery. The mechanisms behind this association are not fully known, but may include increased levels of cytokines and chemokines, host immunosuppression such as increased regulatory T cells, and delayed initiation of adjuvant chemotherapy. Another explanation may be that HH alters the lymphatic drainage route around the GEJ. Normally, lymphatic drainage from the GEJ flows in several directions, namely through perigastric, retroperitoneal, and mediastinal routes. The GEJ is normally located between the positive pressure in the abdomen and the negative pressure in the thorax. However, once the GEJ moves through a HH into the mediastinum, the lymphatic flow may be changed. Flow to the mediastinum may be enhanced due to the negative intra-thoracic pressure. Interestingly, the HH (+) group in this study showed slightly higher recurrence levels in the mediastinal lymph nodes, which might support this hypothesis. Likewise, Maruyama et al investigated the correlation between HH and survival outcomes in patients with proximal gastric or GEJ cancer and suggested that HH may affect the lymphatic drainage. They proposed that the distance between the tumor and the vena caval foramen may be a more accurate parameter to decide the best surgical approach and the extent of lymphadenectomy. Yet another point may be that the higher mediastinal anastomosis possibly will increase the reflux esophagitis or aspiration of pneumonia, which can be one of the causes of death. However, no difference was seen regarding the incidences of pneumonia between the two groups in this study, and pneumonia was not recorded as a cause of death even in the long-term follow-up.

|                                | Hiatal Hernia (+) | Hiatal Hernia (−) | P-value |
|--------------------------------|------------------|------------------|---------|
| **Operative time, min**        | 274.5 (136-511)  | 278.0 (160-370)  | .428    |
| **Blood loss, mL**             | 39.0 (0-876)     | 52.5 (4-981)     | .875    |
| **Additional resection of the esophageal stump** | 9 (19.6%) | 2 (6.3%) | .082    |
| **Intra-abdominal infectious complications** | 11 (23.9%) | 3 (9.4%) | .089    |
| Leakage                        | 2 (4.4%)         | 0                | .143    |
| Abdominal abscess              | 8 (17.4%)        | 1 (3.1%)         | .036    |
| Pancreatic fistula             | 4 (8.7%)         | 2 (6.3%)         | .687    |
| **Other complications**        |                  |                  |         |
| Ileus                          | 3 (5.5%)         | 0                | .052    |
| Pneumonia                      | 6 (11.1%)        | 4 (8.7%)         | .687    |
| Cholecystitis                  | 0                | 1 (2.2%)         | .211    |
| **Postoperative in-hospital days** | 10 (7-60) | 10 (7-57) | .357    |
| Amylase levels of drainage fluid, IU/L | 168 (31-1953) | 122 (21-3044) | .949    |
| Esophageal invasive lengthb, mm | 8.0 (0-37) | 8.5 (0-30) | .343    |
| Tumor size, mm                 | 48.5 (10-137)a   | 57.5 (23-124)a   | .904    |
| Pathological T (1-2/3-4)       | 25 (54.4%)/21 (45.6%) | 16 (50.0%)/16 (50.0%) | .705    |
| Pathological N (−/+|)          | 13 (40.6%)/19 (59.4%) | 23 (50.0%)/23 (50.0%) | .413    |
| Pathological Stage (I/II/III)  | 19 (41.3%)/15 (32.6%)/12 (26.0%) | 11 (34.4%)/10 (31.2%)/11 (34.4%) | .710    |

aMedian (range).
bMeasured by postoperative pathology.
Gastroesophageal junction cancer is likely to be treated in the same way as gastric cancer, especially in East Asia. However, GEJ cancer is well-known to possess unique oncological features due to its anatomy. The general prognosis is reported to be worse in GEJ cancer than in gastric cancer. Moreover, the mechanisms of tumor development are different in these two diseases.
|                         | Overall survival | Relapse-free survival |
|-------------------------|-----------------|---------------------|
|                         | Number | Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis |
|                         | n = 36   | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age, years              |         |              |         |              |         |              |         |
| >75                     | 6       | 1.245 (0.347-4.472) | .741 | 1.232 (0.343-4.427) | .753 |
| ≤75                     | 30      |              |         |              |         |              |         |
| BMI[^a^], kg/m^2        |         |              |         |              |         |              |         |
| >2.7                    | 17      | 1.681 (0.583-4.850) | .332 | 1.661 (0.575-4.791) | .344 |
| ≤22.7                   | 19      |              |         |              |         |              |         |
| Pathological T factor   |         |              |         |              |         |              |         |
| pT3-4                   | 27      | 4.876 (0.636-37.378) | .056 | 5.400 (0.704-41.404) | .039 | 1.209 (0.116-12.560) | .872 |
| pT1-2                   | 9       |              |         |              |         |              |         |
| Pathological N factor   |         |              |         |              |         |              |         |
| pN +                    | 28      | 4.640 (0.606-35.507) | .065 | 5.213 (0.680-39.692) | .044 | 4.704 (0.536-41.296) | .099 |
| pN −                    | 8       |              |         |              |         |              |         |
| Tumor size[^a^], mm     |         |              |         |              |         |              |         |
| >60                     | 22      | 2.553 (0.701-7.242) | .153 | 1.997 (0.624-6.392) | .224 |
| ≤60                     | 14      |              |         |              |         |              |         |
| Histology               |         |              |         |              |         |              |         |
| Undifferentiated        | 6       | 5.653 (1.757-18.191) | .003 | 2.155 (0.580-8.013) | .258 | 5.121 (1.622-16.159) | .011 |
| Differentiated          | 30      |              |         |              |         |              |         |
| Esophageal invasive length, mm |   |              |         |              |         |              |         |
| >20                     | 16      | 4.553 (1.412-14.688) | .011 | 4.813 (1.303-17.774) | .014 | 4.424 (1.371-14.274) | .008 |
| ≤20                     | 20      |              |         |              |         |              |         |
| Adjuvant chemotherapy   |         |              |         |              |         |              |         |
| Yes                     | 28      | 1.620 (0.451-5.815) | .439 | 1.738 (0.484-6.238) | .373 |
| No                      | 8       |              |         |              |         |              |         |
| Presence of hiatal hernia|        |              |         |              |         |              |         |
| HH (+)                  | 17      | 3.055 (1.017-9.176) | .040 | 3.596 (1.086-11.904) | .032 | 2.963 (0.988-8.887) | .046 |
| HH (−)                  | 19      |              |         |              |         |              |         |

Abbreviations: 95% CI, 95% Confidence interval; BMI, Body mass index; HR, Hazard ratio.

[^a^]: The cut-off value was defined by the median.
TABLE 4 Site of recurrence

|                | Hiatal Hernia (+) | Hiatal Hernia (−) | P-value |
|----------------|-------------------|-------------------|---------|
| Overall         | 12 (100%)         | 7 (100%)          | .67     |
| Hematogenous    |                   |                   |         |
| Liver           | 4 (33%)           | 1 (14%)           | .30     |
| Lung            | 4 (33%)           | 3 (43%)           | .91     |
| Peritoneal      | 7 (58%)           | 1 (14%)           | .06     |
| Local           | 0                 | 1 (14%)           | .17     |
| Other           | 1 (8%)            | 1 (14%)           | .79     |

*a-Duplication allowed.

rising incidence of GEJ cancer worldwide, it is crucial to understand the specific prognostic factors for GEJ cancer patients. The results of this study suggest that the presence of HH is an important prognostic factor for patients with GEJ cancer. Additionally, our data suggest that the surgical approach (transhiatal or transthoracic) and extent of lymph node resection should be carefully decided taking into account the presence of HH. In order to confirm the lymphatic flow in real time, some new technologies such as indocyanine green (ICG) fluorescence may be helpful, while we have not applied that in this study.

This study had several limitations. First, this was a single-institution retrospective study. Furthermore, even in high-volume centers, the volume of GEJ cancer surgery is small, which is reflected in the sample size in this study. Second, HH diagnosis, and Makuuchi classification, was made only by endoscopic findings. Particularly in patients with a large tumor diameter or a peripheral lesion, estimating the degree of esophageal hiatal hernia was difficult or inaccurate. To reduce this ambiguity, all patients from grade A to C were included in the HH (+) group in this study. Furthermore, we examined the prognosis stratified to the degree of HH, but neither significant difference nor tendency was seen (data not shown).

In conclusion, HH may adversely affect not only surgical, but also survival outcomes in patients with GEJ. Therefore, specific considerations regarding the surgical approach or the extent of lymph node dissection may be necessary for these patients.

ACKNOWLEDGMENTS

The data sets generated during the current study are not publicly available to protect individual patient information, but data are available from the corresponding author on reasonable request. The authors thank Ms Tamae Takeuchi for her dedicated efforts in preparing the manuscript. We thank Leah Cannon, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

DISCLOSURE

Funding: This study was not supported by any funding source.
Conflict of Interest: The authors declare no conflict of interest.
Ethical Approval: The protocol for this study was approved by the Institutional Review Board and it conforms to the provisions of the Declaration of Helsinki. Informed consent was obtained from all patients included in this study.

ORCID

Yuya Tanaka https://orcid.org/0000-0002-5844-1904
Takahiro Kinoshita https://orcid.org/0000-0001-7365-8733

REFERENCES

1. Bollschweiler E, Wolfarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92(3):549–55.
2. Crew KD, Neugut A. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):450–64.
3. Liu K, Zhang W, Chen X, et al. Comparison on clinicopathological features and prognosis between esophagogastrointestinal junctional adenocarcinoma (Siewert II/III Types) and distal gastric adenocarcinoma: retrospective cohort study, a single institution, high volume experience in China. Medicine. 2015;94(34):e1386.
4. Jung MK, Schmidt T, Chon S-H, Chevallay M, Berlth F, Akiyama J, et al. Current surgical treatment standards for esophageal and esophagogastrectomy junction cancer. Ann N Y Acad Sci. 2020;1482(1):77–84.
5. Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, et al. Mapping of lymph node metastasis from esophagogastrectomy junction tumors: a prospective nationwide multicenter study. Ann Surg. 2021;274(1):120–7.
6. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
7. Yu H-X, Han C-S, Xue J-R, Han Z-F, Xin H. Esophageal hiatal hernia: risk, diagnosis and management. Expert Rev Gastroenterol Hepatol. 2018;12(4):319–29.
8. Hihara J, Hirai T, Yamashita Y, Yoshida K, Kwahara M, Kagawa Y, et al. Poor prognosis in esophageal cancer patients with post-operative complications: surgical oncotaxis. Dis Esophagus. 1999;12(4):152–4.
9. Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198(1):42–50.
10. Walker KG, Bell SW, Rickard MJFX, Mehanna D, Dent OF, Chapuis PH, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004;240(2):255–9.
11. McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005;92(9):1150–4.
12. Makuuchi H. Clinical study of sliding esophageal hernia–with special reference to the diagnostic criteria and classification of the severity of the disease. Nihon Shokakibyo Gakkai Zasshi. 1982;79(8):1557–67.
13. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.
14. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
15. Kumagai Y, Yagi M, Aida J, Ishida H, Suzuki S, Hashimoto T, et al. Detailed features of palisade vessels as a marker of the esophageal mucosa revealed by magnifying endoscopy with narrow band imaging. Dis Esophagus. 2012;25:484–90.

16. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.

17. Yin Q, Wang W, Liu H, Yang G, Zhou S, Liu L, et al. Clinical application and observation of modified Ivor-Lewis surgery in Siewert type II adenocarcinoma of the Esophagogastric junction. J Cardiothorac Surg. 2019;14(1):207.

18. Mine S, Kurokawa Y, Takeuchi H, Kishi K, Ito Y, Ohi M, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol. 2015;41(10):1348–53.

19. Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157(3):551–5.

20. Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, et al. Multi-institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. Cancer Med. 2019;8(11):5194–201.

21. Fujiya K, Tokunaga M, Mori K, Makuuchi R, Tanizawa Y, Bando E, et al. Long-term survival in patients with postoperative intra-abdominal infectious complications after curative gastrectomy for gastric cancer: a propensity score matching analysis. Ann Surg Oncol. 2016;23(5):809–16.

22. Tsujimoto H, Ichikura T, Ono S, Sugawara H, Hiraki S, Sakamoto N, et al. Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol. 2009;16(2):311–8.

23. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer. 2001;92(8):2050–5.

24. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

25. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancer. Clin Cancer Res. 2003;9(12):4404–8.

26. Lu H, Zhao B, Zhang J, Huang R, Wang Z, Xu H, et al. Dose delayed initiation of adjuvant chemotherapy following the curative resection affect the survival outcome of gastric cancer patients: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(6):1103–10.

27. Maruyama S, Kawaguchi Y, Akaike H, Shiraiishi K, Saito R, Shimizu H, et al. Prognostic significance of Hiatal Hernia in patients with gastric cancer located within the upper-third of the stomach. World J Surg. 2020;44(3):863–8.

28. Bruno L, Nesi G, Montinaro F, Carassale G, Lassig R, Boddi V, et al. Clinicopathologic findings and results of surgical treatment in cardiac adenocarcinoma. J Surg Oncol. 2000;74(1):33–5.

29. Ectors N, Driessen A, De Hertog G, Lerut T, Geboes K. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med. 2005;129(2):183–5.

How to cite this article: Tanaka Y, Kinoshita T, Akimoto E, Sato R, Yura M, Harada J, et al. The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma. Ann Gastroenterol Surg. 2022;6:366–374. doi:10.1002/ags3.12540